CELUW
Price:
$0.0152
Market Cap:
$51.26M
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic ...[Read more]
Industry
Biotechnology
IPO Date
2021-07-19
Stock Exchange
NASDAQ
Ticker
CELUW
According to Celularity Inc.’s latest financial reports and current stock price. The company's current ROE is -119.53%. This represents a change of 192.20% compared to the average of -40.91% of the last 4 quarters.
The mean historical ROE of Celularity Inc. over the last ten years is -88.42%. The current -119.53% ROE has changed 35.19% with respect to the historical average. Over the past ten years (40 quarters), CELUW's ROE was at its highest in in the March 2021 quarter at 131.90%. The ROE was at its lowest in in the September 2020 quarter at -344.40%.
Average
-88.42%
Median
1.55%
Minimum
-479.24%
Maximum
39.19%
Discovering the peaks and valleys of Celularity Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.66%
Maximum Annual ROE = 39.19%
Minimum Annual Increase = -6816.49%
Minimum Annual ROE = -479.24%
Year | ROE | Change |
---|---|---|
2023 | -479.24% | -6816.49% |
2022 | 7.14% | -107.09% |
2021 | -100.70% | -356.99% |
2020 | 39.19% | 1.66% |
2019 | 2.23% | 155.81% |
The current ROE of Celularity Inc. (CELUW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-190.93%
5-year avg
-106.28%
10-year avg
-88.42%
Celularity Inc.’s ROE is greater than Celularity Inc. (-119.53%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Quantum-Si incorporated (-37.12%), less than Humacyte, Inc. (1.17%), greater than Surrozen, Inc. (-222.75%),
Company | ROE | Market cap |
---|---|---|
-119.53% | $51.26M | |
2.18% | $2.82K | |
-37.12% | $166.64M | |
1.17% | $238.04M | |
-222.75% | $48.20M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celularity Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Celularity Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Celularity Inc.'s ROE?
How is the ROE calculated for Celularity Inc. (CELUW)?
What is the highest ROE for Celularity Inc. (CELUW)?
What is the 3-year average ROE for Celularity Inc. (CELUW)?
What is the 5-year average ROE for Celularity Inc. (CELUW)?
How does the current ROE for Celularity Inc. (CELUW) compare to its historical average?